Therapeutic Vaccination Targeting Indoleamine-2, 3 Dioxygenase (IDO) Using a IDO Derived Class I Restricted Peptide in Combination with Aldara and Montanide for Patients With Locally Advanced or Metastatic Non Small-Cell Lung Cancer. A First-in-man Phase I Trial

Trine Zeeberg Buch-Hansen; Rikke Bæk Sørensen; A. Mellemgaard; P.T. Straten; M.H. Andersen; I.M. Svane; M.H. Andersen

Therapeutic Vaccination Targeting Indoleamine-2, 3 Dioxygenase (IDO) Using a IDO Derived Class I Restricted Peptide in Combination with Aldara and Montanide for Patients With Locally Advanced or Metastatic Non Small-Cell Lung Cancer. A First-in-man Phase I Trial

Trine Zeeberg Buch-Hansen, Rikke Bæk Sørensen, A. Mellemgaard, P.T. Straten, M.H. Andersen, I.M. Svane, M.H. Andersen

Originalsprog	Engelsk
Tidsskrift	Journal of Immunotherapy
Vol/bind	33
Udgave nummer	8
Sider (fra-til)	919-920
Antal sider	2
ISSN	1524-9557
Status	Udgivet - 2010

FN’s Verdensmål

Dette resultat bidrager til følgende verdensmål

Citationsformater

Buch-Hansen, T. Z., Sørensen, R. B., Mellemgaard, A., Straten, P. T., Andersen, M. H., Svane, I. M., & Andersen, M. H. (2010). Therapeutic Vaccination Targeting Indoleamine-2, 3 Dioxygenase (IDO) Using a IDO Derived Class I Restricted Peptide in Combination with Aldara and Montanide for Patients With Locally Advanced or Metastatic Non Small-Cell Lung Cancer. A First-in-man Phase I Trial. Journal of Immunotherapy, 33(8), 919-920.

Therapeutic Vaccination Targeting Indoleamine-2, 3 Dioxygenase (IDO) Using a IDO Derived Class I Restricted Peptide in Combination with Aldara and Montanide for Patients With Locally Advanced or Metastatic Non Small-Cell Lung Cancer. A First-in-man Phase I Trial. / Buch-Hansen, Trine Zeeberg; Sørensen, Rikke Bæk; Mellemgaard, A. et al.
I: Journal of Immunotherapy, Bind 33, Nr. 8, 2010, s. 919-920.

Publikation: Bidrag til tidsskrift › Konferenceabstrakt i tidsskrift › Forskning › peer review

Buch-Hansen, TZ, Sørensen, RB, Mellemgaard, A, Straten, PT , Andersen, MH , Svane, IM & Andersen, MH 2010, 'Therapeutic Vaccination Targeting Indoleamine-2, 3 Dioxygenase (IDO) Using a IDO Derived Class I Restricted Peptide in Combination with Aldara and Montanide for Patients With Locally Advanced or Metastatic Non Small-Cell Lung Cancer. A First-in-man Phase I Trial', Journal of Immunotherapy, bind 33, nr. 8, s. 919-920.

Buch-Hansen TZ, Sørensen RB, Mellemgaard A, Straten PT , Andersen MH , Svane IM et al. Therapeutic Vaccination Targeting Indoleamine-2, 3 Dioxygenase (IDO) Using a IDO Derived Class I Restricted Peptide in Combination with Aldara and Montanide for Patients With Locally Advanced or Metastatic Non Small-Cell Lung Cancer. A First-in-man Phase I Trial. Journal of Immunotherapy. 2010;33(8):919-920.

Buch-Hansen, Trine Zeeberg ; Sørensen, Rikke Bæk ; Mellemgaard, A. et al. / Therapeutic Vaccination Targeting Indoleamine-2, 3 Dioxygenase (IDO) Using a IDO Derived Class I Restricted Peptide in Combination with Aldara and Montanide for Patients With Locally Advanced or Metastatic Non Small-Cell Lung Cancer. A First-in-man Phase I Trial. I: Journal of Immunotherapy. 2010 ; Bind 33, Nr. 8. s. 919-920.

@article{fbdc7d910baa4a6d9c0116e0e29b280c,

title = "Therapeutic Vaccination Targeting Indoleamine-2, 3 Dioxygenase (IDO) Using a IDO Derived Class I Restricted Peptide in Combination with Aldara and Montanide for Patients With Locally Advanced or Metastatic Non Small-Cell Lung Cancer. A First-in-man Phase I Trial",

author = "Buch-Hansen, {Trine Zeeberg} and S{\o}rensen, {Rikke B{\ae}k} and A. Mellemgaard and P.T. Straten and M.H. Andersen and I.M. Svane and M.H. Andersen",

year = "2010",

language = "English",

volume = "33",

pages = "919--920",

journal = "Journal of Immunotherapy",

issn = "1524-9557",

publisher = "Lippincott Williams & Wilkins",

number = "8",

}

TY - ABST

T1 - Therapeutic Vaccination Targeting Indoleamine-2, 3 Dioxygenase (IDO) Using a IDO Derived Class I Restricted Peptide in Combination with Aldara and Montanide for Patients With Locally Advanced or Metastatic Non Small-Cell Lung Cancer. A First-in-man Phase I Trial

AU - Buch-Hansen, Trine Zeeberg

AU - Sørensen, Rikke Bæk

AU - Mellemgaard, A.

AU - Straten, P.T.

AU - Andersen, M.H.

AU - Svane, I.M.

AU - Andersen, M.H.

PY - 2010

Y1 - 2010

M3 - Conference abstract in journal

SN - 1524-9557

VL - 33

SP - 919

EP - 920

JO - Journal of Immunotherapy

JF - Journal of Immunotherapy

IS - 8

ER -